Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Toshiki Fujioka"'
Publikováno v:
Journal of Neuroinflammation, Vol 20, Iss 1, Pp 1-13 (2023)
Abstract Background Guillain–Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are human autoimmune peripheral neuropathy. Besides humoral immunity, cellular immunity is also believed to contribute to these patholog
Externí odkaz:
https://doaj.org/article/af46bac88af24d4ba6691114d17a4c5e
Autor:
Takahumi Uchi, Shingo Konno, Hideo Kihara, Mari Matsushima, Hideki Sugimoto, Toshiaki Oharaseki, Kei Takahashi, Toshiki Fujioka
Publikováno v:
Case Reports in Neurology, Vol 14, Iss 2, Pp 314-319 (2022)
A 55-year-old woman with a history of allergic sinusitis was being administered cyclosporine for ptosis and diplopia due to myasthenia gravis since age 46 years. She developed painful dysesthesia that began in her feet and later spread to her palms,
Externí odkaz:
https://doaj.org/article/4d64744b620f4e6fac3f9e68dab0351d
Autor:
Shingo Konno, Wataru Hagiwara, Miyuki Sasaki, Akihisa Fuse, Tomomi Imamura, Masashi Inoue, Hisao Kitazono, Toshiki Fujioka
Publikováno v:
Case Reports in Neurology, Vol 6, Iss 1, Pp 88-91 (2014)
A 69-year-old woman presented with generalized myasthenia gravis and a left orbital cavernous hemangioma (OCH), which elevated the optic nerve and displaced the external eye muscles. Cyclosporine treatment induced a gradual size reduction in the OCH,
Externí odkaz:
https://doaj.org/article/a15b1e1dc9d84162939ed493a878ca12
Autor:
Shingo Konno, Shigeaki Suzuki, Masayuki Masuda, Yuriko Nagane, Emiko Tsuda, Hiroyuki Murai, Tomihiro Imai, Toshiki Fujioka, Norihiro Suzuki, Kimiaki Utsugisawa
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126579 (2015)
To investigate the association between glucocorticoid-induced osteoporosis and myasthenia gravis (MG) using a cross-sectional survey in Japan.We studied 363 patients with MG (female 68%; mean age, 57 ± 16 years) who were followed at six Japanese cen
Externí odkaz:
https://doaj.org/article/92c9ff0c0a4845339e38d7f0cb257766
Autor:
Hideki Sugimoto, Shingo Konno, Nobuatsu Nomoto, Hiroshi Nakazora, Mayumi Murata, Hisao Kitazono, Tomomi Imamura, Masashi Inoue, Miyuki Sasaki, Akihisa Fuse, Wataru Hagiwara, Mari Kobayashi, Toshiki Fujioka
Publikováno v:
PLoS ONE, Vol 9, Iss 11, p e113766 (2014)
To examine the impact of the plasma homocysteine level on the anti-atherosclerotic effects of pitavastatin treatment, we retrospectively examined 59 patients who had a history of stroke and had been prescribed pitavastatin for the treatment of dyslip
Externí odkaz:
https://doaj.org/article/134ea08732a344349b68a5ba7584104d
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 2, p319-322, 4p
Autor:
Shingo Konno, Takafumi Uchi, Jun Isonishi, Mari Matsushima, Hideo Kihara, Hideki Sugimoto, Toshiki Fujioka
Publikováno v:
Clinical and Experimental Neuroimmunology. 14:34-43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d2c983d2a65dfca993592bd6429c595
https://doi.org/10.1111/cen3.12723
https://doi.org/10.1111/cen3.12723
Autor:
Shoma Kitano, Toru Awaya, Masao Moroi, Hidehiko Hara, Hideki Itaya, Mari Matsushima, Kei Takahashi, Toshiki Fujioka, Masato Nakamura
Publikováno v:
Canadian Journal of Cardiology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47a1b96cb09b815a35482e31bae5949c
https://doi.org/10.1016/j.cjca.2023.03.016
https://doi.org/10.1016/j.cjca.2023.03.016
Publikováno v:
Internal Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c49ddc487c4778244cee4d6605a1f69d
https://doi.org/10.2169/internalmedicine.1942-23
https://doi.org/10.2169/internalmedicine.1942-23
Publikováno v:
Toho Journal of Medicine. 4(2):49-57
ORIGINAL ARTICLE
Background: The phosphodiesterase-3 inhibitor cilostazol (CLZ) is widely prescribed as an antiplatelet agent in treatment for peripheral arterial disease. The immune modulating effect of CLZ has been unveiled in experimental aut
Background: The phosphodiesterase-3 inhibitor cilostazol (CLZ) is widely prescribed as an antiplatelet agent in treatment for peripheral arterial disease. The immune modulating effect of CLZ has been unveiled in experimental aut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=jairo_______::57b15b662904ae62e78a7d11a87349c6
https://mylibrary.toho-u.ac.jp/webopac/TD56753913
https://mylibrary.toho-u.ac.jp/webopac/TD56753913